ERBB2 and breast carcinoma: Increasing levels of TILs have been associated with improved therapy outcome in HER2+ breast cancer and/or TNBC patients treated with adjuvant (11–15), neoadjuvant chemotherapy (16–18) and monoclonal antibodies blocking programmed death-1 (PD-1) (19).